Skip to content
2000
image of Chalcones as Multi-target Ligands for Alzheimer's Disease: A Review of Synthetic Strategies and Therapeutic Promise

Abstract

Introduction

Alzheimer’s disease remains a multifactorial neurodegenerative disorder with limited therapeutic options. Chalcones, flavonoid-derived molecules with high structural flexibility and diverse biological activities, have emerged as promising candidates due to their ability to inhibit Aβ aggregation and cholinesterase activity. Recent research highlights their relevance as multi-target agents suitable for early-stage drug discovery.

Methods

This review compiled and analyzed studies published between 2022 and 2025 on chalcones and their derivatives with anti-Alzheimer’s potential. Data were extracted regarding biosynthetic origins, synthetic strategies, physicochemical properties, and biological activities, including inhibitory potencies against AChE, MAO-B, and Aβ aggregation.

Results

Numerous chalcone-based compounds exhibited significant activity against key Alzheimer’s disease targets, such as Aβ aggregation (up to 78.2% inhibition) and enzymatic inhibition (, AChE IC = 11.6 nM; MAO-B IC = 92 nM). Their structural versatility enabled the identification of potent derivatives with multi-target effects, addressing oxidative stress, amyloid pathology, and cholinergic dysfunction.

Discussion

Chalcones represent a privileged scaffold suitable for medicinal chemistry optimization, offering ease of synthesis and adaptable chemical space for structure–activity relationship exploration. Their multi-target nature aligns with the complexity of Alzheimer’s disease. However, challenges remain, including selectivity, pharmacokinetics, and translation from preclinical models to therapeutic relevance.

Conclusion

Chalcones and their derivatives show strong preclinical promise as multi-target agents for Alzheimer’s disease. Continued structural optimization and biological evaluation may advance these compounds toward disease-modifying therapies, supporting their potential role in future drug discovery efforts.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575436583251223100249
2026-02-20
2026-03-02

  • From This Site

    /content/journals/mrmc/10.2174/0113895575436583251223100249
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Piñero J. Temporal R.M. Silva-Gonçalves A.J. Jiménez I.A. Bazzocchi I.L. Oliva A. Perera A. Leon L.L. Valladares B. New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis. Acta Trop. 2006 98 1 59 65 10.1016/j.actatropica.2006.02.001 16529707
    [Google Scholar]
  2. Díaz-Tielas C. Graña E. Reigosa M.J. Sánchez-Moreiras A.M. Biological activities and novel applications of chalcones. Planta Daninha 2016 34 3 607 616 10.1590/s0100‑83582016340300022
    [Google Scholar]
  3. Ludovico G.S. Barros I.H.S. Sallum L.O. Lima R.S. Valverde C. Camargo A.J. Baseia B. Napolitano H.B. A new isostructural halogenated chalcone with optical properties. J. Mol. Model. 2021 27 2 52 10.1007/s00894‑021‑04673‑9 33502611
    [Google Scholar]
  4. Rocha J.E. de Freitas T.S. Xavier J.C. Pereira R.L.S. Pereira Junior F.N. Nogueira C.E.S. Marinho M.M. Bandeira P.N. Rodrigues L.G. Marinho E.S. de Lacerda B.C.G.V. de Andrade E.M. Teixeira A.M.R. dos Santos H.S. Coutinho H.D.M. ADMET study, spectroscopic characterization and effect of synthetic nitro chalcone in combination with norfloxacin, ciprofloxacin, and ethidium bromide against Staphylococcus aureus efflux pumps. Fundam. Clin. Pharmacol. 2023 37 1 163 173 10.1111/fcp.12830 36082507
    [Google Scholar]
  5. Cho Y.C. Lee S.H. Yoon G. Kim H.S. Na J.Y. Choi H.J. Cho C.W. Cheon S.H. Kang B.Y. Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-κB. Int. Immunopharmacol. 2010 10 9 1119 1126 10.1016/j.intimp.2010.06.015 20601178
    [Google Scholar]
  6. Muto E. Okada T. Yamanaka T. Uchino H. Inazu M. Licochalcone E. Licochalcone E, a β-amyloid aggregation inhibitor, regulates microglial m1/m2 polarization via inhibition of CTL1-mediated choline uptake. Biomolecules 2023 13 2 191 10.3390/biom13020191 36830561
    [Google Scholar]
  7. Zhang Q. Zhang J. Liu B. Wei J. Licochalcone E inhibits trxR1 expression, alters Nrf2/STAT6 signal, and induces antitumor effects in vitro against human SH-SY5Y and SK-N-BE (2) neuroblastoma cells. Environ. Toxicol. 2022 37 5 1173 1184 10.1002/tox.23474 35092341
    [Google Scholar]
  8. Han J. Wang D. Li D. Chen X. Wang B. Wang F. Liu X. Shang J. Zheng Q. Licochalcone E protects against carbon tetrachloride-induced liver toxicity by activating peroxisome proliferator-activated receptor gamma. Mol. Med. Rep. 2017 16 4 5269 5276 10.3892/mmr.2017.7268 28849019
    [Google Scholar]
  9. Dewick P.M. Medicinal Natural Products: A Biosynthetic Approach. Hoboken, New Jersey Wiley Online Library 2009
    [Google Scholar]
  10. Dao T.T.H. Linthorst H.J.M. Verpoorte R. Chalcone synthase and its functions in plant resistance. Phytochem. Rev. 2011 10 3 397 412 10.1007/s11101‑011‑9211‑7 21909286
    [Google Scholar]
  11. Rudrapal M. Khan J. Dukhyil A.A.B. Alarousy R.M.I.I. Attah E.I. Sharma T. Khairnar S.J. Bendale A.R. Chalcone scaffolds, bioprecursors of flavonoids: Chemistry, bioactivities, and pharmacokinetics. Molecules 2021 26 23 7177 10.3390/molecules26237177 34885754
    [Google Scholar]
  12. Zhou K. Yang S. Li S.M. Naturally occurring prenylated chalcones from plants: Structural diversity, distribution, activities and biosynthesis. Nat. Prod. Rep. 2021 38 12 2236 2260 10.1039/D0NP00083C 33972962
    [Google Scholar]
  13. Antoniolli G. Almeida W.P. Frias C.C. de Oliveira T.B. Chalcones acting as inhibitors of cholinesterases, β-secretase and β-amyloid aggregation and other targets for Alzheimer’s Disease: A critical review. Curr. Med. Chem. 2021 28 21 4259 4282 10.2174/0929867327666201020151804 33081667
    [Google Scholar]
  14. Constantinescu T. Lungu C.N. Anticancer activity of natural and synthetic chalcones. Int. J. Mol. Sci. 2021 22 21 11306 10.3390/ijms222111306 34768736
    [Google Scholar]
  15. Adelusi T.I. Du L. Chowdhury A. Xiaoke G. Lu Q. Yin X. Signaling pathways and proteins targeted by antidiabetic chalcones. Life Sci. 2021 284 118982 10.1016/j.lfs.2020.118982 33387581
    [Google Scholar]
  16. Salehi B. Quispe C. Chamkhi I. El Omari N. Balahbib A. Sharifi-Rad J. Bouyahya A. Akram M. Iqbal M. Docea A.O. Caruntu C. Leyva-Gómez G. Dey A. Martorell M. Calina D. López V. Les F. Pharmacological properties of chalcones: A review of preclinical including molecular mechanisms and clinical evidence. Front. Pharmacol. 2021 11 592654 10.3389/fphar.2020.592654 33536909
    [Google Scholar]
  17. Mphahlele M.J. Maluleka M.M. Choong Y.S. Monchusi B.A. Mbazima V.G. An in vitro study of the 5-methyl- and 5-bromo/chloro substituted 2-hydroxy-3-nitrochalcones as α-glucosidase and/or α-amylase inhibitors with potential anti-inflammatory activity. Med. Chem. Res. 2022 31 12 2243 2259 10.1007/s00044‑022‑02980‑1
    [Google Scholar]
  18. Li M. Lu G. Ma X. Wang R. Chen X. Yu Y. Jiang C. Anti-inflammation of isoliquiritigenin via the inhibition of NF-κB and MAPK in LPS-stimulated MAC-T cells. BMC Vet. Res. 2022 18 1 320 10.1186/s12917‑022‑03414‑1 35986317
    [Google Scholar]
  19. Qi W.H. Zhang Y.Y. Xing K. Hao D.X. Zhang F. Wang R.N. Bao M.Y. Tian M.Y. Yang Y.N. Li X. Zhang Y. 2′, 4′-Dihydroxy-2,3-dimethoxychalcone: A pharmacological inverse agonist of RORγt ameliorating Th17-driven inflammatory diseases by regulating Th17/Treg. Int. Immunopharmacol. 2022 108 108769 10.1016/j.intimp.2022.108769 35453073
    [Google Scholar]
  20. Okolo E.N. Ugwu D.I. Ezema B.E. Ndefo J.C. Eze F.U. Ezema C.G. Ezugwu J.A. Ujam O.T. New chalcone derivatives as potential antimicrobial and antioxidant agent. Sci. Rep. 2021 11 1 21781 10.1038/s41598‑021‑01292‑5 34741131
    [Google Scholar]
  21. Xavier J.C. de Almeida-Neto F.W.Q. Rocha J.E. Freitas T.S. Freitas P.R. de Araújo A.C.J. da Silva P.T. Nogueira C.E.S. Bandeira P.N. Marinho M.M. Marinho E.S. Kumar N. Barreto A.C.H. Coutinho H.D.M. Julião M.S.S. dos Santos H.S. Teixeira A.M.R. Spectroscopic analysis by NMR, FT-Raman, ATR-FTIR, and UV-Vis, evaluation of antimicrobial activity, and in silico studies of chalcones derived from 2-hydroxyacetophenone. J. Mol. Struct. 2021 1241 130647 10.1016/j.molstruc.2021.130647
    [Google Scholar]
  22. Okoye I. Yu S. Caruso F. Rossi M. X-ray structure determination, antioxidant voltammetry studies of Butein and 2′,4′-dihydroxy-3,4-dimethoxychalcone. Computational studies of 4 structurally related 2′,4′-diOH chalcones to examine their antimalarial activity by binding to Falcipain-2. Molecules 2021 26 21 6511 10.3390/molecules26216511 34770920
    [Google Scholar]
  23. Zhou B. Wang H. Zhang B. Zhang L. Licochalcone B attenuates neuronal injury through anti-oxidant effect and enhancement of Nrf2 pathway in MCAO rat model of stroke. Int. Immunopharmacol. 2021 100 108073 10.1016/j.intimp.2021.108073 34454290
    [Google Scholar]
  24. Hassan R.M. Aboutabl M.E. Bozzi M. El-Behairy M.F. El Kerdawy A.M. Sampaolese B. Desiderio C. Vincenzoni F. Sciandra F. Ghannam I.A.Y. Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPARα agonists with anti-hyperlipidemic and antioxidant activities: Design, synthesis and in vitro/in vivo biological evaluation. Bioorg. Chem. 2021 115 105170 10.1016/j.bioorg.2021.105170 34332233
    [Google Scholar]
  25. Leal A.L.A.B. Pinheiro D.P. Barros-Nepomuceno F.W.A. da Silva P.T. Pessoa C. Almeida-Neto F.W.Q. Marinho E.S. Barreto A.C.H. Julião M.S.S. de Paiva A.S. Bandeira P.N. de Lima-Neto P. dos Santos H.S. Teixeira A.M.R. Structural and spectroscopic analysis and evaluation of cytotoxic activity of 2-hydroxychalcones against human cancer cell lines. J. Mol. Struct. 2021 1245 131135 10.1016/j.molstruc.2021.131135
    [Google Scholar]
  26. Tripathi D. Kulkarni S. Butein induces intrinsic pathway of apoptosis, vimentin proteolysis, and inhibition of cancer stem cell population in a human papillary thyroid cancer cell line. Toxicol. In Vitro 2021 77 105244 10.1016/j.tiv.2021.105244 34481015
    [Google Scholar]
  27. Ibrahim T.S. Malebari A.M. Mohamed M.F.A. Design, synthesis, in vitro anticancer evaluation and molecular modelling studies of 3,4,5-trimethoxyphenyl-based derivatives as dual EGFR/HDAC Hybrid Inhibitors. Pharmaceuticals 2021 14 11 1177 10.3390/ph14111177 34832959
    [Google Scholar]
  28. Díaz-Carrillo J.T. Díaz-Camacho S.P. Delgado-Vargas F. Rivero I.A. López-Angulo G. Sarmiento-Sánchez J.I. Montes-Avila J. Synthesis of leading chalcones with high antiparasitic, against Hymenolepis nana, and antioxidant activities. Braz. J. Pharm. Sci. 2018 10.1590/s2175‑97902018000317343
    [Google Scholar]
  29. Borsari C. Santarem N. Torrado J. Olías A.I. Corral M.J. Baptista C. Gul S. Wolf M. Kuzikov M. Ellinger B. Witt G. Gribbon P. Reinshagen J. Linciano P. Tait A. Costantino L. Freitas-Junior L.H. Moraes C.B. Bruno dos Santos P. Alcântara L.M. Franco C.H. Bertolacini C.D. Fontana V. Tejera Nevado P. Clos J. Alunda J.M. Cordeiro-da-Silva A. Ferrari S. Costi M.P. Methoxylated 2′-hydroxychalcones as antiparasitic hit compounds. Eur. J. Med. Chem. 2017 126 1129 1135 10.1016/j.ejmech.2016.12.017 28064141
    [Google Scholar]
  30. Liou C.J. Lee Y.K. Ting N.C. Chen Y.L. Shen S.C. Wu S.J. Huang W.C. Protective effects of Licochalcone A ameliorates obesity and non-alcoholic fatty liver disease via promotion of the Sirt-1/AMPK Pathway in mice fed a high-fat diet. Cells 2019 8 5 447 10.3390/cells8050447 31083505
    [Google Scholar]
  31. Hsieh C.T. Chang F.R. Tsai Y.H. Wu Y.C. Hsieh T.J. 2-Bromo-4′-methoxychalcone and 2-iodo-4′-methoxychalcone prevent progression of hyperglycemia and obesity via 5′-Adenosine-Monophosphate-Activated Protein Kinase in diet-induced obese mice. Int. J. Mol. Sci. 2018 19 9 2763 10.3390/ijms19092763 30223438
    [Google Scholar]
  32. Higgs J. Wasowski C. Marcos A. Jukič M. Paván C.H. Gobec S. de Tezanos Pinto F. Colettis N. Marder M. Chalcone derivatives: Synthesis, in vitro and in vivo evaluation of their anti-anxiety, anti-depression and analgesic effects. Heliyon 2019 5 3 01376 10.1016/j.heliyon.2019.e01376 30949609
    [Google Scholar]
  33. Labib M.B. Sharkawi S.M.Z. El-Daly M. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: Anti-inflammatory, analgesic activities and docking study. Bioorg. Chem. 2018 80 70 80 10.1016/j.bioorg.2018.05.018 30005203
    [Google Scholar]
  34. Escrivani D.O. Charlton R.L. Caruso M.B. Burle-Caldas G.A. Borsodi M.P.G. Zingali R.B. Arruda-Costa N. Palmeira-Mello M.V. de Jesus J.B. Souza A.M.T. Abrahim-Vieira B. Freitag-Pohl S. Pohl E. Denny P.W. Rossi-Bergmann B. Steel P.G. Chalcones identify cTXNPx as a potential antileishmanial drug target. PLoS Negl. Trop. Dis. 2021 15 11 0009951 10.1371/journal.pntd.0009951 34780470
    [Google Scholar]
  35. Souza J.M. de Carvalho É.A.A. Candido A.C.B.B. de Mendonça R.P. Fernanda da Silva M. Parreira R.L.T. Dias F.G.G. Ambrósio S.R. Arantes A.T. da Silva Filho A.A. Nascimento A.N. Costa M.R. Sairre M.I. Veneziani R.C.S. Magalhães L.G. Licochalcone A exhibits leishmanicidal activity in vitro and in experimental model of Leishmania (Leishmania) infantum. Front. Vet. Sci. 2020 7 527 10.3389/fvets.2020.00527 33363224
    [Google Scholar]
  36. Duran N. Polat M.F. Aktas D.A. Alagoz M.A. Ay E. Cimen F. Tek E. Anil B. Burmaoglu S. Algul O. New chalcone derivatives as effective against SARS-CoV-2 agent. Int. J. Clin. Pract. 2021 75 12 14846 10.1111/ijcp.14846 34519118
    [Google Scholar]
  37. Cao Y. Lei E. Wang X. Qi X. Li L. Ren J. Yang J. Wang S. Licochalcone A inhibits enterovirus A71 replication in vitro and in vivo. Antiviral Res. 2021 195 105091 10.1016/j.antiviral.2021.105091 34044060
    [Google Scholar]
  38. Claisen L. Claparède A. Condensationen von Ketonen mit Aldehyden. Ver. Dtsch. Chem. Ges 1881 14 2 2460 2468 10.1002/cber.188101402192
    [Google Scholar]
  39. Abbott A. Dementia: A problem for our age. Nature 2011 475 7355 S2 S4 10.1038/475S2a 21760579
    [Google Scholar]
  40. 2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024 20 5 3708 3821 10.1002/alz.13809 38689398
    [Google Scholar]
  41. Verheijen J. Sleegers K. Understanding Alzheimer Disease at the interface between genetics and transcriptomics. Trends Genet. 2018 34 6 434 447 10.1016/j.tig.2018.02.007 29573818
    [Google Scholar]
  42. DeTure M.A. Dickson D.W. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 2019 14 1 32 10.1186/s13024‑019‑0333‑5 31375134
    [Google Scholar]
  43. Sosa-Ortiz A.L. Acosta-Castillo I. Prince M.J. Epidemiology of dementias and Alzheimer’s disease. Arch. Med. Res. 2012 43 8 600 608 10.1016/j.arcmed.2012.11.003 23159715
    [Google Scholar]
  44. Zhang X.X. Tian Y. Wang Z.T. Ma Y.H. Tan L. Yu J.T. The epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. J. Prev. Alzheimers Dis. 2021 8 3 313 321 10.14283/jpad.2021.15 34101789
    [Google Scholar]
  45. Teixeira A.L. Rocha N.P. Gatchel J. Behavioral or neuropsychiatric symptoms of Alzheimer’s disease: From psychopathology to pharmacological management. Arq. Neuropsiquiatr. 2023 81 12 1152 1162 10.1055/s‑0043‑1777774 38157881
    [Google Scholar]
  46. Safiri S. Ghaffari Jolfayi A. Fazlollahi A. Morsali S. Sarkesh A. Daei Sorkhabi A. Golabi B. Aletaha R. Motlagh Asghari K. Hamidi S. Mousavi S.E. Jamalkhani S. Karamzad N. Shamekh A. Mohammadinasab R. Sullman M.J.M. Şahin F. Kolahi A.A. Alzheimer’s disease: A comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. Front. Med. 2024 11 1474043 10.3389/fmed.2024.1474043 39736972
    [Google Scholar]
  47. Anand R. Gill K.D. Mahdi A.A. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology 2021 76 Pt A 27 50 10.1016/j.neuropharm.2013.07.004 23891641
    [Google Scholar]
  48. Janus C. Westaway D. Transgenic mouse models of Alzheimer’s disease. Physiol. Behav. 2001 73 5 873 886 10.1016/S0031‑9384(01)00524‑8 11566220
    [Google Scholar]
  49. Kung H.F. The β-amyloid hypothesis in Alzheimer’s disease: Seeing is believing. ACS Med. Chem. Lett. 2012 3 4 265 267 10.1021/ml300058m 24936237
    [Google Scholar]
  50. Dahlgren K.N. Manelli A.M. Stine W.B. Baker L.K. Krafft G.A. LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 2002 277 35 32046 32053 10.1074/jbc.M201750200 12058030
    [Google Scholar]
  51. Kravenska Y. Nieznanska H. Nieznanski K. Lukyanetz E. Szewczyk A. Koprowski P. The monomers, oligomers, and fibrils of amyloid-β inhibit the activity of mitoBKCa channels by a membrane-mediated mechanism. Biochim. Biophys. Acta Biomembr. 2020 1862 9 183337 10.1016/j.bbamem.2020.183337 32380169
    [Google Scholar]
  52. Zatta P. Drago D. Bolognin S. Sensi S.L. Alzheimer’s disease, metal ions and metal homeostatic therapy. Trends Pharmacol. Sci. 2009 30 7 346 355 10.1016/j.tips.2009.05.002 19540003
    [Google Scholar]
  53. Basheer N. Smolek T. Hassan I. Liu F. Iqbal K. Zilka N. Novak P. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials. Mol. Psychiatry 2023 28 6 2197 2214 10.1038/s41380‑023‑02113‑z 37264120
    [Google Scholar]
  54. Rawat P. Sehar U. Bisht J. Selman A. Culberson J. Reddy P.H. Phosphorylated tau In Alzheimer’s disease and other tauopathies. Int. J. Mol. Sci. 2022 23 21 12841 10.3390/ijms232112841 36361631
    [Google Scholar]
  55. Soeda Y. Yoshimura H. Bannai H. Koike R. Shiiba I. Takashima A. Intracellular tau fragment droplets serve as seeds for tau fibrils. Structure 2024 32 10 1793 1807.e6 10.1016/j.str.2024.06.018 39032487
    [Google Scholar]
  56. Kuznetsov I.A. Kuznetsov A.V. How the formation of amyloid plaques and neurofibrillary tangles may be related: A mathematical modelling study. Proc.- Royal Soc., Math. Phys. Eng. Sci. 2018 474 2210 20170777 10.1098/rspa.2017.0777 29507520
    [Google Scholar]
  57. Gaggelli E. Kozlowski H. Valensin D. Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer’s prion, and Parkinson’s diseases and amyotrophic lateral sclerosis). Chem. Rev. 2006 106 6 1995 2044 10.1021/cr040410w 16771441
    [Google Scholar]
  58. Bolognin S. Messori L. Drago D. Gabbiani C. Cendron L. Zatta P. Aluminum, copper, iron and zinc differentially alter amyloid-Aβ1–42 aggregation and toxicity. Int. J. Biochem. Cell Biol. 2011 43 6 877 885 10.1016/j.biocel.2011.02.009 21376832
    [Google Scholar]
  59. Zhu Z. Song M. Ren J. Liang L. Mao G. Chen M. Copper homeostasis and cuproptosis in central nervous system diseases. Cell Death Dis. 2024 15 11 850 10.1038/s41419‑024‑07206‑3 39567497
    [Google Scholar]
  60. Trofin D.M. Sardaru D.P. Trofin D. Onu I. Tutu A. Onu A. Onită C. Galaction A.I. Matei D.V. Oxidative stress in brain function. Antioxidants 2025 14 3 297 10.3390/antiox14030297 40227270
    [Google Scholar]
  61. Simunkova M. Alwasel S.H. Alhazza I.M. Jomova K. Kollar V. Rusko M. Valko M. Management of oxidative stress and other pathologies in Alzheimer’s disease. Arch. Toxicol. 2019 93 9 2491 2513 10.1007/s00204‑019‑02538‑y 31440798
    [Google Scholar]
  62. Chen Z-R. Huang J-B. Yang S-L. Hong F-F. Role of cholinergic signaling in Alzheimer’s Disease. Molecules 2022 27 6 1816 10.3390/molecules27061816 35335180
    [Google Scholar]
  63. Dawson T.M. Golde T.E. Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat. Neurosci. 2018 21 10 1370 1379 10.1038/s41593‑018‑0236‑8 30250265
    [Google Scholar]
  64. Zhang J. Zhang Y. Wang J. Xia Y. Zhang J. Chen L. Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct. Target. Ther. 2024 9 1 211 10.1038/s41392‑024‑01911‑3 39174535
    [Google Scholar]
  65. Singh A.A. Khan F. Song M. Alleviation of neurological disorders by targeting neurodegenerative-associated enzymes: Natural and synthetic molecules. Int. J. Mol. Sci. 2025 26 10 4707 10.3390/ijms26104707 40429850
    [Google Scholar]
  66. Hossain M.S. Hussain M.H. Multi-target drug design in Alzheimer’s disease treatment: Emerging technologies, advantages, challenges, and limitations. Pharmacol. Res. Perspect. 2025 13 4 70131 10.1002/prp2.70131 40531439
    [Google Scholar]
  67. Hardy J. Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002 297 5580 353 356 10.1126/science.1072994 12130773
    [Google Scholar]
  68. Klein W.L. Stine W.B. Teplow D.B. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol. Aging 2004 25 5 569 580 10.1016/j.neurobiolaging.2004.02.010 15172732
    [Google Scholar]
  69. Caramello A. Fancy N. Tournerie C. Eklund M. Chau V. Adair E. Papageorgopoulou M. Willumsen N. Jackson J.S. Hardy J. Matthews P.M. Intracellular accumulation of amyloid-ß is a marker of selective neuronal vulnerability in Alzheimer’s disease. Nat. Commun. 2025 16 1 5189 10.1038/s41467‑025‑60328‑w 40467545
    [Google Scholar]
  70. Oddo S. Caccamo A. Tran L. Lambert M.P. Glabe C.G. Klein W.L. LaFerla F.M. Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of alzheimer disease. J. Biol. Chem. 2006 281 3 1599 1604 10.1074/jbc.M507892200 16282321
    [Google Scholar]
  71. Zemek F. Drtinova L. Nepovimova E. Sepsova V. Korabecny J. Klimes J. Kuca K. Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin. Drug Saf. 2014 13 6 759 774 10.1517/14740338.2014.914168 24845946
    [Google Scholar]
  72. Folch J. Busquets O. Ettcheto M. Sánchez-López E. Castro-Torres R.D. Verdaguer E. Garcia M.L. Olloquequi J. Casadesús G. Beas-Zarate C. Pelegri C. Vilaplana J. Auladell C. Camins A. Memantine for the Treatment of Dementia: A review on its current and future applications. J. Alzheimers Dis. 2018 62 3 1223 1240 10.3233/JAD‑170672 29254093
    [Google Scholar]
  73. Cummings J. Osse A.M.L. Cammann D. Powell J. Chen J. Anti-amyloid monoclonal antibodies for the treatment of alzheimer’s disease. BioDrugs 2024 38 1 5 22 10.1007/s40259‑023‑00633‑2 37955845
    [Google Scholar]
  74. Yang H.M. Recent advances in antibody therapy for Alzheimer’s disease: Focus on Bispecific Antibodies. Int. J. Mol. Sci. 2025 26 13 6271 10.3390/ijms26136271 40650049
    [Google Scholar]
  75. Grøntvedt G.R. Schröder T.N. Sando S.B. White L. Bråthen G. Doeller C.F. Alzheimer’s disease. Curr. Biol. 2018 28 11 R645 R649 10.1016/j.cub.2018.04.080 29870699
    [Google Scholar]
  76. Jedrziewski M.K. Lee V.M.Y. Trojanowski J.Q. Lowering the risk of Alzheimer’s disease: Evidence-Based Practices emerge from new research. Alzheimers Dement. 2005 1 2 152 160 10.1016/j.jalz.2005.09.007 19595848
    [Google Scholar]
  77. Shen Y. Li R. What do we know from clinical trials on exercise and Alzheimer’s disease? J. Sport Health Sci. 2016 5 4 397 399 10.1016/j.jshs.2016.10.002 29130020
    [Google Scholar]
  78. Li G. Teng G. Zhang W. Song T. Li Y. Wang Z. Chen A. Comparative effects of different physical exercises on cognitive function and intervention adherence in older adults with cognitive impairment: A systematic review and network meta-analysis. Clin. Psychol. Rev. 2025 120 102604 10.1016/j.cpr.2025.102604 40466426
    [Google Scholar]
  79. Szabo-Reed A.N. Key M.N. A narrative review evaluating diet and exercise as complementary medicine for the management of Alzheimer’s Disease. Nutrients 2025 17 11 1804 10.3390/nu17111804 40507072
    [Google Scholar]
  80. Antoniolli G. Lima C.S.P. Coelho F. Recent advances in the investigation of the quinazoline nucleus and derivatives with potential anticancer activities. Future Med. Chem. 2025 17 10 1193 1211 10.1080/17568919.2025.2507558 40444391
    [Google Scholar]
  81. Sang Z. Song Q. Cao Z. Deng Y. Zhang L. Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer’s disease. J. Enzyme Inhib. Med. Chem. 2022 37 1 69 85 10.1080/14756366.2021.1993845 34894968
    [Google Scholar]
  82. Burmaoglu S. Kazancioglu E.A. Kazancioglu M.Z. Sağlamtaş R. Yalcin G. Gulcin I. Algul O. Synthesis, molecular docking and some metabolic enzyme inhibition properties of biphenyl-substituted chalcone derivatives. J. Mol. Struct. 2022 1254 132358 10.1016/j.molstruc.2022.132358
    [Google Scholar]
  83. Liu Y. Han C. Dai R. Li B. Rational design, synthesis and activities of hydroxylated chalcones as highly potent dual functional agents against Alzheimer’s disease. Bioorg. Chem. 2022 122 105662 10.1016/j.bioorg.2022.105662 35276602
    [Google Scholar]
  84. Arslan T. Senturk M. Karagoz L. Karagoz Y. Ekinci D. Efe A. Türkoğlu E.A. Uras F. Synthesis, in vitro and in silico biological studies of sulfonamide chalcones as esterase inhibitors. ChemistrySelect 2022 7 44 202202993 10.1002/slct.202202993
    [Google Scholar]
  85. El-Damasy A.K. Park J.E. Kim H.J. Lee J. Bang E.K. Kim H. Keum G. Identification of new N-methyl-piperazine chalcones as dual MAO-B/AChE Inhibitors. Pharmaceuticals 2023 16 1 83 10.3390/ph16010083 36678580
    [Google Scholar]
  86. Hasan A.H. Shakya S. Hussain F.H.S. Murugesan S. Chander S. Pratama M.R.F. Jamil S. Das B. Biswas S. Jamalis J. Design, synthesis, anti-acetylcholinesterase evaluation and molecular modelling studies of novel coumarin-chalcone hybrids. J. Biomol. Struct. Dyn. 2023 41 21 11450 11462 10.1080/07391102.2022.2162583 36591704
    [Google Scholar]
  87. Chen R. Li X. Chen H. Wang K. Xue T. Mi J. Ban Y. Zhu G. Zhou Y. Dong W. Tang L. Sang Z. Development of the “hidden” multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2023 251 115253 10.1016/j.ejmech.2023.115253 36921526
    [Google Scholar]
  88. Sharma P. Singh V. Singh M. N -methylpiperazinyl and piperdinylalkyl-O -chalcone derivatives as potential polyfunctional agents against Alzheimer’s disease: Design, synthesis and biological evaluation. Chem. Biol. Drug Des. 2023 102 5 1155 1175 10.1111/cbdd.14318 37599098
    [Google Scholar]
  89. Abdalla Ali A. Mhamad S.A. Hasan A.H. Ahmad I. Abdullah S.A. Jamil S. Patel H. Murugesan S. Jamalis J. Synthesis, biological evaluation and molecular modeling studies of modulated benzyloxychalcones as potential acetylcholinesterase inhibitors. J. Biomol. Struct. Dyn. 2024 42 7 3604 3615 10.1080/07391102.2023.2220032 37293930
    [Google Scholar]
  90. Gop R.S. Adhikary R. Venkatramani A. Sengar N. Singh I.P. Panda D. 4-Amino-3′,4′-dihydroxychalcone increases Tau dynamics in phase-separated droplets and inhibits Tau aggregation. ACS Chem. Neurosci. 2025 16 9 1680 1693 10.1021/acschemneuro.4c00567 40226980
    [Google Scholar]
  91. Sang Z. Bai P. Ban Y. Wang K. Wu A. Mi J. Hu J. Xu R. Zhu G. Wang J. Zhang J. Wang C. Tan Z. Tang L. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer’s agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies. Bioorg. Chem. 2022 127 106007 10.1016/j.bioorg.2022.106007 35849893
    [Google Scholar]
  92. Ceyhun İ. Karaca Ş. Osmaniye D. Sağlık B.N. Levent S. Özkay Y. Kaplancıklı Z.A. Design and synthesis of novel chalcone derivatives and evaluation of their inhibitory activities against acetylcholinesterase. Arch. Pharm. 2022 355 3 2100372 10.1002/ardp.202100372 34893996
    [Google Scholar]
  93. Li X. Li Y. Liu Z. Zhang Q. Zhou Y. Yu L. Liu W. Sang Z. Development of novel chalcone derivatives as multifunctional agents for the treatment of Alzheimer’s disease. Med. Chem. Res. 2024 33 3 548 561 10.1007/s00044‑024‑03196‑1
    [Google Scholar]
  94. Hasan A.H. Murugesan S. Amran S.I. Chander S. Alanazi M.M. Hadda T.B. Shakya S. Pratama M.R.F. Das B. Biswas S. Jamalis J. Novel thiophene Chalcones-Coumarin as acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, molecular docking, ADMET prediction and molecular dynamics simulation. Bioorg. Chem. 2022 119 105572 10.1016/j.bioorg.2021.105572 34971946
    [Google Scholar]
  95. Şenol H. Ghaffari-Moghaddam M. Alim Toraman G.Ö. Güller U. Novel chalcone derivatives of ursolic acid as acetylcholinesterase inhibitors: Synthesis, characterization, biological activity, ADME prediction, molecular docking and molecular dynamics studies. J. Mol. Struct. 2024 1295 136804 10.1016/j.molstruc.2023.136804
    [Google Scholar]
  96. Nadeem M.S. Khan J.A. Kazmi I. Moglad E. Afzal M. Alzarea S.I. Rahim F. Khan S. Muhammad K. Gupta G. Synthesis D.F.T. Synthesis, DFT, ADMET and molecular docking studies of thiazole derived thiazolidinone-based chalcone derivatives: Alzheimer’s disease current therapies. Future Med. Chem. 2024 1 9 10.1080/17568919.2024.2421158 39628307
    [Google Scholar]
  97. Kumar H. Goyal A. Kumar N. Garg P. Design, synthesis, and biological evaluation of pyrazolo-benzothiazole derivatives as a potential therapeutic agent for the treatment of Alzheimer’s disease. Med. Chem. Res. 2022 31 11 1931 1947 10.1007/s00044‑022‑02953‑4
    [Google Scholar]
  98. Abdelwahab H.E. Ibrahim H.Z. Omar A.Z. Design, synthesis, DFT, molecular docking, and biological evalution of pyrazole derivatives as potent acetyl cholinestrease inhibitors. J. Mol. Struct. 2023 1271 134137 10.1016/j.molstruc.2022.134137
    [Google Scholar]
  99. Bajad N.G. Jangra J. T A, G.; Kumar, A.; Krishnamurthy, S.; Singh, S.K. Discovery of pyrazoline analogs as multi-targeting cholinesterase, β-secretase and Aβ aggregation inhibitors through lead optimization strategy. Int. J. Biol. Macromol. 2025 301 140436 10.1016/j.ijbiomac.2025.140436 39884636
    [Google Scholar]
  100. Taha M. Sadia H. Rahim F. Khan M.I. Hayat S. Iqbal N. Nawaz F. Ullah H. Zada H. Shah S.A.A. Wadood A. Farooq R.K. Khan K.M. Synthesis, biological evaluation and molecular docking study of oxindole based chalcone analogues as potent anti-Alzheimer agents. J. Mol. Struct. 2023 1285 135530 10.1016/j.molstruc.2023.135530
    [Google Scholar]
/content/journals/mrmc/10.2174/0113895575436583251223100249
Loading
Chalcones as Multi-target Ligands for Alzheimer's Disease: A Review of Synthetic Strategies and Therapeutic Promise
Bentham Science Publishers ; https://doi.org/10.2174/0113895575436583251223100249
/content/journals/mrmc/10.2174/0113895575436583251223100249
/content/journals/mrmc/10.2174/0113895575436583251223100249
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: privileged scaffolds ; biological activity ; Chalcone ; therapeutic potential ; bioactive compounds ; Alzheimer’s disease ; drug discovery

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test